JP2018534932A5 - - Google Patents

Download PDF

Info

Publication number
JP2018534932A5
JP2018534932A5 JP2018522662A JP2018522662A JP2018534932A5 JP 2018534932 A5 JP2018534932 A5 JP 2018534932A5 JP 2018522662 A JP2018522662 A JP 2018522662A JP 2018522662 A JP2018522662 A JP 2018522662A JP 2018534932 A5 JP2018534932 A5 JP 2018534932A5
Authority
JP
Japan
Prior art keywords
polypeptide
activity
ion
small molecule
assay
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018522662A
Other languages
English (en)
Japanese (ja)
Other versions
JP7064769B2 (ja
JP2018534932A (ja
Filing date
Publication date
Priority claimed from PCT/US2016/019242 external-priority patent/WO2016138071A1/en
Application filed filed Critical
Priority claimed from PCT/US2016/049715 external-priority patent/WO2017078839A1/en
Publication of JP2018534932A publication Critical patent/JP2018534932A/ja
Publication of JP2018534932A5 publication Critical patent/JP2018534932A5/ja
Priority to JP2022068158A priority Critical patent/JP7390748B2/ja
Application granted granted Critical
Publication of JP7064769B2 publication Critical patent/JP7064769B2/ja
Priority to JP2023193435A priority patent/JP2024020382A/ja
Priority to JP2025185767A priority patent/JP2026027333A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018522662A 2015-11-02 2016-08-31 条件的活性型ポリペプチド Active JP7064769B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022068158A JP7390748B2 (ja) 2015-11-02 2022-04-18 条件的活性型ポリペプチド
JP2023193435A JP2024020382A (ja) 2015-11-02 2023-11-14 条件的活性型ポリペプチド
JP2025185767A JP2026027333A (ja) 2015-11-02 2025-11-04 条件的活性型ポリペプチド

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562249907P 2015-11-02 2015-11-02
US62/249,907 2015-11-02
USPCT/US2016/019242 2016-02-24
PCT/US2016/019242 WO2016138071A1 (en) 2015-02-24 2016-02-24 Conditionally active biological proteins
PCT/US2016/049715 WO2017078839A1 (en) 2015-11-02 2016-08-31 Conditionally active polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022068158A Division JP7390748B2 (ja) 2015-11-02 2022-04-18 条件的活性型ポリペプチド

Publications (3)

Publication Number Publication Date
JP2018534932A JP2018534932A (ja) 2018-11-29
JP2018534932A5 true JP2018534932A5 (https=) 2019-10-10
JP7064769B2 JP7064769B2 (ja) 2022-05-11

Family

ID=58662272

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018522662A Active JP7064769B2 (ja) 2015-11-02 2016-08-31 条件的活性型ポリペプチド
JP2022068158A Active JP7390748B2 (ja) 2015-11-02 2022-04-18 条件的活性型ポリペプチド
JP2023193435A Pending JP2024020382A (ja) 2015-11-02 2023-11-14 条件的活性型ポリペプチド
JP2025185767A Pending JP2026027333A (ja) 2015-11-02 2025-11-04 条件的活性型ポリペプチド

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022068158A Active JP7390748B2 (ja) 2015-11-02 2022-04-18 条件的活性型ポリペプチド
JP2023193435A Pending JP2024020382A (ja) 2015-11-02 2023-11-14 条件的活性型ポリペプチド
JP2025185767A Pending JP2026027333A (ja) 2015-11-02 2025-11-04 条件的活性型ポリペプチド

Country Status (10)

Country Link
US (2) US11472876B2 (https=)
EP (1) EP3371349A1 (https=)
JP (4) JP7064769B2 (https=)
KR (2) KR102714709B1 (https=)
CN (2) CN115521374B (https=)
AU (2) AU2016350613B2 (https=)
CA (1) CA3003399A1 (https=)
MX (2) MX2018005063A (https=)
RU (1) RU2735023C9 (https=)
WO (1) WO2017078839A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2913205T3 (es) * 2014-05-13 2022-06-01 Bioatla Inc Proteínas biológicas activas condicionalmente
WO2017078839A1 (en) * 2015-11-02 2017-05-11 Bioatla, Llc Conditionally active polypeptides
US10697972B2 (en) 2016-01-12 2020-06-30 Bioatla, Llc Diagnostics using conditionally active antibodies
EP3403098B1 (en) * 2016-01-12 2021-09-22 BioAtla, Inc. Diagnostics using conditionally active antibodies
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
AU2017320874B2 (en) * 2016-08-31 2024-03-07 Bioatla, Llc Conditionally active polypeptides and methods of generating them
KR20250159733A (ko) 2017-01-11 2025-11-11 브리스톨-마이어스 스큅 컴퍼니 Psgl-1 길항제 및 그의 용도
JP7280827B2 (ja) 2017-01-18 2023-05-24 エクスマ バイオテック コーポレイション Ａｘｌまたはｒｏｒ２に対するキメラ抗原受容体およびその使用方法
PE20250933A1 (es) 2017-03-14 2025-04-02 Five Prime Therapeutics Inc Anticuerpos de union a vista a ph acido
BR112020019083A2 (pt) 2018-03-21 2020-12-29 Five Prime Therapeutics, Inc. Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer
WO2019241216A1 (en) * 2018-06-14 2019-12-19 Bioatla, Llc Multi-specific antibody constructs
PE20210687A1 (es) 2018-07-11 2021-04-08 Bristol Myers Squibb Co Anticuerpos de union a vista a ph acido
WO2020041247A1 (en) * 2018-08-21 2020-02-27 Bioatla, Llc CONDITIONALLY ACTIVE PROTEINS WITH pH SELECTIVITY
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN113924118A (zh) 2019-04-18 2022-01-11 百时美施贵宝公司 在低ph下具有增强的结合特异性的伊匹单抗变体
US12391745B2 (en) * 2020-06-15 2025-08-19 Sarepta Therapeutics, Inc. Adeno-associated virus antibodies and fragments thereof
EP4168452A4 (en) * 2020-06-18 2024-07-10 BioAtla, Inc. Conditionally active anti-cd46 antibodies, antibody fragments, their immunoconjugates and uses thereof
CN115768798A (zh) * 2020-06-18 2023-03-07 生物蛋白有限公司 条件活性抗粘附分子-4(nectin-4)抗体
EP4651894A2 (en) * 2023-01-18 2025-11-26 Harpoon Therapeutics, Inc. Her2 targeting trispecific protein for treatment of cancer
JP2026507181A (ja) * 2023-03-02 2026-02-27 バイオアトラ インコーポレイテッド 条件的活性型抗ＥｐＣＡＭ抗体、抗体断片及びそれを組み込んだ構築物

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
WO1992010591A1 (en) 1990-12-14 1992-06-25 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
CA2100671C (en) 1991-02-27 1999-02-02 James S. Huston Serine rich peptide linkers
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
GB9320668D0 (en) 1993-10-07 1993-11-24 Secr Defence Liposomes containing particulare materials
HUT76369A (en) 1994-07-29 1997-08-28 Smithkline Beecham Corp Novel soluble protein compounds
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
EP1658772A3 (en) 1995-01-17 2007-01-17 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
AU6330896A (en) 1995-06-07 1996-12-30 Governors Of The University Of Alberta, The A method for eliciting a th1-specific immune response
US6764835B2 (en) 1995-12-07 2004-07-20 Diversa Corporation Saturation mutageneis in directed evolution
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP4772958B2 (ja) 1998-02-09 2011-09-14 ブラッコ・リサーチ・ソシエテ・アノニム 生物学的に活性な媒質の標的に向けた送達
US7112324B1 (en) 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
US6573050B1 (en) * 1999-10-29 2003-06-03 Sunnybrook & Women's College Health Sciences Centre Treatment, diagnosis and evaluation of anti-cancer therapy resistance in melanoma
US20020028178A1 (en) 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
AU6461201A (en) 2000-07-12 2002-01-21 Idec Pharma Corp Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
JP2004508420A (ja) 2000-09-18 2004-03-18 アイデック　ファーマスーティカルズ　コーポレイション Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法
US20040136908A1 (en) 2001-04-09 2004-07-15 Olson William C. Anti-cd19 immunotoxins
US20030138405A1 (en) 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways
DK1381402T3 (da) 2001-04-27 2010-03-08 Vivoxid Oy Fremgangsmåde til forbedring af blødvævsmodtagelse og implantater der gør brug af denne fremgangsmåde
EP1436119B2 (de) 2001-10-17 2008-08-13 Schneider GmbH + Co. KG Vorrichtung und verfahren zur komplettbearbeitung von zweiseitig optisch aktiven linsen
US20060147420A1 (en) 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
US20060141456A1 (en) * 2002-06-12 2006-06-29 Cynthia Edwards Methods and compositions for milieu-dependent binding of a targeted agent to a target
US20040064050A1 (en) 2002-09-20 2004-04-01 Jun Liu System and method for screening tissue
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US20050260711A1 (en) * 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
AU2005285347A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US8961877B2 (en) 2007-08-09 2015-02-24 Massachusetts Institute Of Technology High-throughput, whole-animal screening system
JP2010068746A (ja) 2008-09-18 2010-04-02 Chiba Univ 抗腫瘍効果を有する化合物の同定方法
RU2636046C2 (ru) 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Композиции модифицированных антител, способы их получения и применения
CN102369296A (zh) * 2009-03-09 2012-03-07 生物蛋白有限公司 Mirac蛋白
SG10201700096VA (en) 2009-07-17 2017-02-27 Bioatla Llc Simultaneous, Integrated Selection And Evolution Of Antibody/Protein Performance And Expression In Production Hosts
US20110143960A1 (en) 2009-12-10 2011-06-16 Labarbera Daniel V 3d-models for high-throughput screening drug discovery and development
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
MX349622B (es) * 2010-09-08 2017-08-07 Halozyme Inc Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas.
WO2013040445A1 (en) 2011-09-15 2013-03-21 Whitehead Institute For Biomedical Research Arrays for cell-based screening and uses thereof
KR102276528B1 (ko) 2011-09-30 2021-07-12 추가이 세이야쿠 가부시키가이샤 이온 농도 의존성 결합 분자 라이브러리
AU2013229786B2 (en) * 2012-03-08 2017-06-22 Halozyme, Inc. Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
US20140206596A1 (en) * 2013-01-18 2014-07-24 University Of Southern California Design of pH-Sensitive Oligopeptide Complexes For Drug Release Under Mildly Acidic Conditions
ES2913205T3 (es) 2014-05-13 2022-06-01 Bioatla Inc Proteínas biológicas activas condicionalmente
WO2017078839A1 (en) * 2015-11-02 2017-05-11 Bioatla, Llc Conditionally active polypeptides
AU2017320874B2 (en) * 2016-08-31 2024-03-07 Bioatla, Llc Conditionally active polypeptides and methods of generating them

Similar Documents

Publication Publication Date Title
JP2018534932A5 (https=)
RU2018115781A (ru) Условно активные полипептиды
JP2020536488A5 (https=)
HRP20251020T1 (hr) Proteini s jednolančanim varijabilnim fragmentom koji vežu cd3
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
JP2018521638A5 (https=)
JP2014518883A5 (https=)
AR072897A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
JP2016196468A5 (https=)
JP2019529350A5 (https=)
RU2012131671A (ru) Способ полипептидной модификации для очистки полипептидных мультимеров
RU2017117596A (ru) Связывающие молекулы, специфичные в отношении CD73, и пути их применения
CL2008003004A1 (es) Anticuerpo anti-esclerostina o su porción de enlace de antígeno; polinucleotido que lo codifica; vector; célula; proceso de producción; composición farmacéutica que lo comprende; método para identificar células y su uso para tratar trastornos óseos.
JP7619939B2 (ja) 原発性免疫不全症、シスチン症、及びウィルソン病に関する新生児スクリーニング
Lu et al. Frontier of therapeutic antibody discovery: The challenges and how to face them
WO2019235915A8 (en) Methods and means for attracting immune effector cells to tumor cells
US11970543B2 (en) Anti-CD39 antibodies and use thereof
JP2021517459A5 (https=)
IL273578B1 (en) Antibodies targeting pdl1 and methods of use thereof
JP2017538412A5 (https=)
WO2024086617A3 (en) Ph-dependent anti-cd3 antibodies and methods relating thereto
EP3103810A3 (en) Modified variable domain molecules and methods for producing and using them
WO2021112676A3 (en) Methods and means for attracting immune effector cells to tumor cells
AR095499A1 (es) ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b
PE20240224A1 (es) Anticuerpo biespecifico anti-tspan8/anti-cd3 y anticuerpo anti-tspan8